the study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.
Non-invasive prolactinomas were treated by transsphenoidal surgery or Dopamine agonist until now. However，this two type therapies were controversial. The study aim to investigate the endocrine remission rate of non-invasive prolactinoma between transsphenoidal surgery treatment and Dopamine agonist treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
394
transsphenoidal surgery treatment
Minimum effective dose of dopamine agonist，bromocriptine，treat prolactinona
Sun Yat-sen 5010 program
Guangzhou, China
RECRUITINGEndocrine remission rate
After intervention, blood prolactin normalization rate
Time frame: five-year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.